Galmed Pharma Reports Aramchol Study Results
Ticker: GLMD · Form: 6-K · Filed: Nov 18, 2025 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial-results, press-release, drug-development
TL;DR
GALMED announces positive Aramchol study results, filing 6-K with press release.
AI Summary
On November 18, 2025, Galmed Pharmaceuticals Ltd. announced meaningful top-line results from its AM-001 study of Aramchol Meglumine. The company filed a Form 6-K to report this development, attaching the press release as Exhibit 99.1.
Why It Matters
This announcement provides an update on the clinical trial progress for Aramchol Meglumine, a key drug candidate for Galmed Pharmaceuticals.
Risk Assessment
Risk Level: medium — Clinical trial results can be highly impactful, and the market reaction to these 'meaningful' results will determine the immediate risk.
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- Aramchol Meglumine (drug) — Drug being studied
- AM-001 (study) — Clinical trial name
- November 18, 2025 (date) — Date of press release
FAQ
What specific 'meaningful top line results' were announced for the AM-001 study of Aramchol Meglumine?
The filing states that meaningful top-line results were announced, but the specific details are contained within the attached press release (Exhibit 99.1), which is not provided in this text.
What is the primary purpose of filing a Form 6-K for Galmed Pharmaceuticals Ltd. in this instance?
The Form 6-K was filed to report the issuance of a press release on November 18, 2025, announcing the study results, as required for foreign private issuers.
What is Aramchol Meglumine?
Aramchol Meglumine is the drug candidate being studied in the AM-001 trial, as indicated by the press release title.
When was the press release announcing the study results issued?
The press release was issued on November 18, 2025.
Where is Galmed Pharmaceuticals Ltd. based?
Galmed Pharmaceuticals Ltd. is based in Ramat Gan, Israel, as indicated by the address provided.
Filing Stats: 194 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-11-18 08:48:45
Filing Documents
- form6-k.htm (6-K) — 16KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-25-024004.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: November 18, 2025 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer